Akari Therapeutics Deal History & Licensing Activity
Akari Therapeutics is a biotech headquartered in Sweden. Over the past three years, Akari Therapeutics has been involved in 1 licensing and acquisition transaction, with a primary focus on ADC (2 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
ADC
Focus Area
Mega Deals
Akari Therapeutics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Akari Therapeutics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ADC development and manufacturing | Akari | ADC | Unknown | collaboration | Apr 2026 |
Akari Therapeutics Pipeline Focus
Therapeutic areas and modalities where Akari Therapeutics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Akari Therapeutics Strategic Signals
Key indicators of Akari Therapeutics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
See How Your Asset Matches Akari Therapeutics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Akari Therapeutics Licensing & Deal Activity
Akari Therapeutics is a biotech company based in Sweden that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Akari Therapeutics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Akari Therapeutics include Mega Deals (2 deals and trials). In terms of modality, Akari Therapeutics has shown particular interest in adc.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Akari Therapeutics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Akari Therapeutics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.